IBRXActive

Will IBRX Q2 2026 net product revenue exceed $45 million?

Resolves August 15, 2026(151d)

IG: 0.72

Current Prediction

72%

Likely Yes

Model Agreement82%

Predictions9 runs

Last UpdatedMarch 17, 2026

Why This Question Matters

Revenue trajectory is the central question for both commercial viability and financing leverage. The Gravy Gauge flagged CONDITIONAL durability with growth dependent on continued adoption. If Q2 revenue exceeds $45M (continuing 15%+ QoQ growth), it validates the adoption thesis and strengthens financing position. If growth decelerates below this level, it signals approaching market ceiling.

REVENUE_DURABILITYFUNDING_FRAGILITY

Prediction Distribution

0%25%50%75%100%

opus

sonnet

haiku

Range: 68% – 78%Aggregate: 72%

Individual Predictions(9 runs)

opusRun 1

75%

Q4 2025 revenue was $38.3M with 20% QoQ growth. If Q1 sustains even 15% QoQ growth (~$44M), Q2 at $45M requires only ~2% incremental growth. The 750% unit volume growth and physician adoption suggest the launch curve is still early. BCG shortage tailwind persists.

Q4 QoQ growth 20%Unit volume growth 750%BCG shortage tailwind

opusRun 2

70%

Sequential growth from $38.3M to $45M over two quarters implies ~8.5% CAGR per quarter. Given 20% QoQ in Q4, this is actually a deceleration from recent trend. The addressable market ceiling (~5K patients) provides headroom for 2-3 more quarters of strong growth before saturation effects.

Deceleration from 20% QoQ still achieves targetAddressable market not yet saturatedSequential momentum

opusRun 3

72%

Revenue trajectory strongly supports crossing $45M by Q2. Key risk is gross-to-net adjustments as payer mix evolves with more government program patients. Also monitoring whether any BCG supply normalization reduces urgency for ANKTIVA adoption.

Strong trajectoryGross-to-net risk as payer mix evolvesBCG supply normalization risk

sonnetRun 1

78%

This is essentially asking whether adoption continues for two more quarters. With no competition in BCG-unresponsive NMIBC, ongoing BCG shortages, and expanding physician awareness, continued growth is the base case. $45M by Q2 is conservative relative to the Q4 run rate.

No competitionBCG shortageExpanding physician awareness

sonnetRun 2

73%

Revenue momentum is strong but $45M represents cumulative growth requiring sustained execution. Seasonality in bladder cancer diagnosis patterns could affect quarterly cadence. No guidance from management adds uncertainty.

Revenue momentum strongPotential seasonalityNo forward guidance

sonnetRun 3

68%

The growth is real but launching biologics often see S-curve dynamics. The question is whether we are still on the steep part of the curve or approaching the inflection. With <2 years of data, difficult to model precisely. Slightly lower confidence due to limited history.

S-curve dynamics uncertaintyLimited commercial historyStill early in adoption curve

haikuRun 1

72%

20% QoQ growth in Q4, 750% unit volume growth, no competition. Trajectory clearly supports $45M+ by Q2 2026. Main risk is unexpected event (safety signal, supply disruption).

Strong trajectoryNo competitionUnexpected event risk

haikuRun 2

68%

Revenue growth is adoption-driven and accelerating. $45M in Q2 would be ~17% above Q4 over two quarters. Achievable given current trends but not certain. Assign ~70% probability.

Adoption-driven growth17% cumulative growth targetAchievable but uncertain

haikuRun 3

70%

Strong revenue trajectory, physician adoption confirmed, BCG shortage provides tailwind. Q2 $45M threshold is reasonable. Moderate confidence at 70%.

Strong trajectoryPhysician adoptionBCG shortage tailwind

Resolution Criteria

Resolves YES if IBRX reports Q2 2026 (quarter ending June 30, 2026) net product revenue of $45 million or more in its 10-Q or earnings press release.

Resolution Source

IBRX 10-Q for Q2 2026 or earnings press release

Source Trigger

ANKTIVA quarterly revenue growth rate below 10% QoQ

gravy-gaugeREVENUE_DURABILITYHIGH

View IBRX Analysis

Full multi-lens equity analysis